Kairos Pharma Ltd (KAPA) Stock Price, Quote & News

Company Profile

Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The company develops KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune respons...

Industry: Biotechnology

Sector: Healthcare

Phone: 310-948-2356

Website: kairospharma.com

Address:

2355 Westwood Boulevard, Suite 139, Los Angeles, United States

ezcheezie Oct. 27 at 2:03 PM

$KAPA Someone knows something. 2 big buys pre-market. Should we see some good movement this week?

0 · Reply

Landomos Oct. 24 at 2:42 PM

$KAPA Folks this is a great company doing great research. Doing my DD and loading.

0 · Reply

FreddieMercury91 Oct. 24 at 2:08 PM

$KAPA steady climb, alerted at 1.03. my team and i are rolling in wins

0 · Reply

stockforce123 Oct. 23 at 7:10 PM

$KAPA https://s204.q4cdn.com/681232979/files/doc_presentations/2025/10/kairos-deck.pdf

0 · Reply

stockforce123 Oct. 23 at 7:03 PM

$KAPA New company presentation. Just published. https://s204.q4cdn.com/681232979/files/doc_presentations/2025/10/kairos-deck.pdf

0 · Reply

TB85 Oct. 23 at 6:34 PM

$KAPA Nice to see we defended the one dolla line. And now, can we get some partnership-news? Like to see that analyst-pricetarget hit before X-mas!

0 · Reply

FreddieMercury91 Oct. 23 at 2:16 PM

$KAPA bought at 1.03 yesterday. likes to go to the 1.30 range

0 · Reply

stockforce123 Oct. 22 at 11:50 PM

$KAPA Just keep this in your heart: “cancer patients’ lives are being saved by Kairos Pharma every single day as we are watching this stock being traded at this level”. It’s Kairos time, it’s in the universe.

0 · Reply

SPYmyQQQ Oct. 22 at 8:03 PM

🚀 New Signal ✅ 💊 $KAPA 🗓️ Oct 22, 2025 💵 Entry: $1.08 🎯 Target (Opt.): $1.26 (+16.67%) 👉 FREE TRIAL! Check bio.

0 · Reply

ChrisBAB Oct. 22 at 7:33 PM

$KAPA Great entry point. Everything is on sale today!

0 · Reply

Kairos Pharma Presents on Phase 2 Trial of ENV-105 in Advanced Prostate Cancer at European Society Medical Oncologists (ESMO) Meeting

Oct 7, 2025, 8:00 AM EDT - 20 days ago

Kairos Pharma to Present Positive Safety and Efficacy Data from Phase 2 Prostate Cancer Trial at ESMO 2025

Sep 18, 2025, 8:00 AM EDT - 5 weeks ago

Kairos Pharma Announces Positive Interim Efficacy Analysis of Phase 2 Trial of ENV105 in Advanced Prostate Cancer with Median Progression Free Survival of Over One Year

Sep 11, 2025, 8:00 AM EDT - 6 weeks ago

Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer

Sep 3, 2025, 8:15 AM EDT - 7 weeks ago

Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025

Sep 2, 2025, 4:05 PM EDT - 7 weeks ago

Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Jul 28, 2025, 12:28 PM EDT - 3 months ago

CEO.CA's Inside the Boardroom: Kairos Pharma CEO on Phase 2 Safety Data, 165% Stock Move & September Efficacy Timeline

Jul 16, 2025, 8:30 AM EDT - 3 months ago

Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

Jul 15, 2025, 2:08 PM EDT - 3 months ago

Why Is Kairos Pharma Stock Surging On Tuesday?

Jul 15, 2025, 8:00 AM EDT - 3 months ago

Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer

Jun 3, 2025, 8:15 AM EDT - 5 months ago

Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

May 6, 2025, 8:00 AM EDT - 6 months ago

Kairos Pharma, Ltd. Announces Participation in the D.

Apr 28, 2025, 8:00 AM EDT - 6 months ago

Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

Apr 24, 2025, 8:00 AM EDT - 6 months ago

Kairos Pharma Ltd. Provides Letter to Stockholders

Apr 17, 2025, 8:00 AM EDT - 6 months ago

Kairos Pharma Ltd. Announces Department of Defense Grant to Support Its Study of Lead Compound ENV105 to Prevent Drug Resistance in Lung Cancer

Mar 31, 2025, 7:00 AM EDT - 7 months ago

Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer

Mar 27, 2025, 4:05 PM EDT - 7 months ago

Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events

Mar 20, 2025, 7:30 AM EDT - 7 months ago

Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer

Feb 26, 2025, 7:00 AM EST - 8 months ago

Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds' Potential as Therapeutics for Melanoma and Glioblastoma

Feb 18, 2025, 8:30 AM EST - 8 months ago

Kairos Pharma Announces New Department of Defense Funding for Research of ENV205

Feb 11, 2025, 8:30 AM EST - 9 months ago

Kairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical Trial

Feb 6, 2025, 8:30 AM EST - 9 months ago

Kairos Pharma Oral Presentation on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference Supports the Compound's Potential as a Therapeutic for Melanoma and Glioblastoma

Jan 28, 2025, 8:15 AM EST - 9 months ago

Kairos Pharma to Present Short Talk on Its Investigational Compound KROS 101 at the 13th AACR-JCA Joint Conference February 5, 2024

Jan 21, 2025, 8:30 AM EST - 9 months ago

Kairos Pharma Provides Business Update and Outlook into 2025

Jan 7, 2025, 8:15 AM EST - 10 months ago

Kairos Pharma to Present at the Lytham Partners Investor Healthcare Summit

Dec 26, 2024, 7:51 AM EST - 10 months ago

Kairos Pharma: Potential To Remove Resistance With Established Drugs

Dec 16, 2024, 12:15 PM EST - 11 months ago

Kairos Pharma to Participate in The Microcap Conference in January 2025

Dec 3, 2024, 8:30 AM EST - 11 months ago

Kairos Pharma Adds City of Hope Cancer Center for Phase 2 ENV105 Clinical Trial

Nov 26, 2024, 8:30 AM EST - 11 months ago

IBN Initiates Coverage of Kairos Pharma Ltd.

Oct 22, 2024, 9:00 AM EDT - 1 year ago

Kairos Pharma to Present at the LD Micro Main Event XVII

Oct 9, 2024, 4:30 PM EDT - 1 year ago

Kairos Pharma to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Sep 24, 2024, 4:20 PM EDT - 1 year ago

Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients

Sep 21, 2024, 2:00 AM EDT - 1 year ago

U.S. IPO Weekly Recap: 2 Microcaps List As Pipeline Gets A Big Boost

BIOA BKV FBGL GLE GRDN LGCY PRB

Sep 17, 2024, 4:29 PM EDT - 1 year ago

Kairos Pharma Closing of $6.2 Million Initial Public Offering

Sep 16, 2024, 10:49 AM EDT - 1 year ago

Kairos Pharma Prices $6.2 Million Initial Public Offering

Feb 14, 2024, 6:16 PM EST - 1 year ago

Kairos Pharma to sell 1.55 million shares in IPO at $4 each

Oct 3, 2023, 3:33 PM EDT - 2 years ago

Kairos Pharma Files For U.S. IPO

ezcheezie Oct. 27 at 2:03 PM

$KAPA Someone knows something. 2 big buys pre-market. Should we see some good movement this week?

0 · Reply

Landomos Oct. 24 at 2:42 PM

$KAPA Folks this is a great company doing great research. Doing my DD and loading.

0 · Reply

FreddieMercury91 Oct. 24 at 2:08 PM

$KAPA steady climb, alerted at 1.03. my team and i are rolling in wins

0 · Reply

stockforce123 Oct. 23 at 7:10 PM

$KAPA https://s204.q4cdn.com/681232979/files/doc_presentations/2025/10/kairos-deck.pdf

0 · Reply

stockforce123 Oct. 23 at 7:03 PM

$KAPA New company presentation. Just published. https://s204.q4cdn.com/681232979/files/doc_presentations/2025/10/kairos-deck.pdf

0 · Reply

TB85 Oct. 23 at 6:34 PM

$KAPA Nice to see we defended the one dolla line. And now, can we get some partnership-news? Like to see that analyst-pricetarget hit before X-mas!

0 · Reply

FreddieMercury91 Oct. 23 at 2:16 PM

$KAPA bought at 1.03 yesterday. likes to go to the 1.30 range

0 · Reply

stockforce123 Oct. 22 at 11:50 PM

0 · Reply

SPYmyQQQ Oct. 22 at 8:03 PM

🚀 New Signal ✅ 💊 $KAPA 🗓️ Oct 22, 2025 💵 Entry: $1.08 🎯 Target (Opt.): $1.26 (+16.67%) 👉 FREE TRIAL! Check bio.

0 · Reply

ChrisBAB Oct. 22 at 7:33 PM

$KAPA Great entry point. Everything is on sale today!

0 · Reply

OrangeJoolius Oct. 22 at 6:19 PM

$KAPA Should also point out the market is blood red right now. Only 2 out of 20 stocks on my watchlist are barely green. Everything is deep red today. Don't panic sell on days like today, you only regret it later.

1 · Reply

TB85 Oct. 22 at 4:49 PM

$KAPA They have to feed us/the stock with something! If not, im kinda worried it will drop back in the 0,60-0,70s again.

2 · Reply

LazyJoey Oct. 22 at 4:05 PM

$KAPA This stock is dropping like caca caca 💩

0 · Reply

OrangeJoolius Oct. 22 at 3:34 PM

$KAPA Was waiting for today to start building my position. Had a feeling that once nothing came of the conference people would dump and move on. Still too much long term potential here to not hold a small core position, so I'm picking up handfuls at a time on the way down.

1 · Reply

joaneegell Oct. 22 at 2:25 PM

$KAPA jesus christ this stock breaks my black little heart

0 · Reply

stockforce123 Oct. 21 at 10:39 PM

$KAPA “The presentation at ESMO has increased the visibility of ENV-105 within the oncology community, which may attract interest in partnerships or strategic collaborations.” https://prismmarketview.com/kairos-pharma-announces-promising-interim-results-for-env-105-in-advanced-prostate-cancer-trial/

0 · Reply

TB85 Oct. 21 at 6:19 PM

$KAPA So, for lack of anything else! What triggers do we have to look forward to?? Besides "dream-rocket-triggers" such as partnership and licensing deals.

2 · Reply

Kono6 Oct. 21 at 4:50 PM

$KAPA uptrend has already started since this post. Should run up nicely like KAPA did as it approaches this date

1 · Reply

ezcheezie Oct. 21 at 3:42 PM

$KAPA No volume, no action. Load up on the dips and ride it out to 10 $$

0 · Reply

stockforce123 Oct. 20 at 8:27 PM

$KAPA $10 by the EOY

1 · Reply

j123321 Oct. 20 at 7:37 PM

$KAPA Why people are dumping it ??

0 · Reply

j123321 Oct. 20 at 7:34 PM

$KAPA Too many news and this didn't flinch a bit :(

0 · Reply

Market Cap	22.61M
Revenue (ttm)	0.00
Net Income (ttm)	-2.60M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	302,140
Avg Vol	1,138,518
Day's Range	N/A - N/A
Shares Out	20.74M
Stochastic %K	24%
Beta	N/A
Analysts	Strong Sell
Price Target	$8.33